1e
In Memoriam
16
19
1
49
2
2
18
1b
1d
18
2c
2b
7
61
1d
2 29
1d
25
Toshio Asakura
88
2b
7
61
Department: Pediatrics
4
1
b
1d
46
Contact information
44
4
3
3
3
2
4
b
1f
44
Division of Hematology
24 Room 316G Abramson Building
30 The Children's Hospital of Philadelphia
41 34th St. & Civic Center Blvd.
Philadelphia, PA 19104
26
24 Room 316G Abramson Building
30 The Children's Hospital of Philadelphia
41 34th St. & Civic Center Blvd.
Philadelphia, PA 19104
2c
Office: 2159779779
30
8f
30
Email:
ASAKURAT@EMAIL.CHOP.EDU
12
ASAKURAT@EMAIL.CHOP.EDU
13
Education:
21 9 B.S. 16 ((Biology)) c
3f Kyotofuritsu University, Kyoto, Japan , 1956.
21 9 M.D. 18 ( (Medicine)) c
35 Kyoto Medical College, Japan, 1960.
21 a Ph.D. 1b ((Biochemistry)) c
30 Tokyo University, Japan, 1965.
c
3
3
3
3
8b
Permanent link21 9 B.S. 16 ((Biology)) c
3f Kyotofuritsu University, Kyoto, Japan , 1956.
21 9 M.D. 18 ( (Medicine)) c
35 Kyoto Medical College, Japan, 1960.
21 a Ph.D. 1b ((Biochemistry)) c
30 Tokyo University, Japan, 1965.
c
2 29
21
1e
1d
24
2b
29
27
23
bb Iyamu, E.W. and Asakura, T. : Drug Therapy for sickle cell disease. Exp. Opin. Ther. Patents. 13: 807-813, 2003.
179 Iyamu, E.W., Adunyah, S.E., Fasold, H., Horiuchi, K. Baliga, S. Ohene-Frempong, K., Turner, E.A., and Asakura, T. : Combined Use of Non-myelosuppressive Nitrosourea Analogues with Hydroxyurea in the Induction of F-cells production in a Human Erythroleukemic cell line. Exp. Hematol. 31: 592-600, 2003.
13a Iyamu, E.W., Turner, E.A. and Asakura, T. : The naturally occurring antisickling agent, Nix-0699, prolongs the survival time of transgenic sickle cell mice exposed to acute severe hypoxic conditions. Brit J Haematol . 122: 1001-1008, 2003.
139 Abdulmalik, O., Martin, M., Yang, J., Chen, Q., Brugnara, C., Evans, G., Abraham, D. and Asakura, T.: In vitro and in vivo studies on 5-hydroxymethyl-2-furfural (5HMF): A new potent antisickling agent. American Society of Hematology 2003.
d6 Iyamu W.E: In vitro effects of NIPRISAN (Nix-0699): a naturally occirring potent antisickling agent. Brit. J. Haematol. 118: 337-343, 2002.
179 Zhang, C., Li, X., Lian, L., Q. Chen, L.Q., Vassilev, V., C. Lai, C., Evans G, and Asakura, T: Antisickling effect of MX-1520, A prodrug of vanillin: an in vitro study using rats and transgenic sickle mice. The 26 th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
1a6 sakura, T., Ballas, S., Ohene-Frempong, K., and Lian L. : Existence of two types of reversibly sickled cells in the blood of patients with sickle cell disease: their involvment in the clinical diversity among patients and initiation of vaso-occlusion. The 26th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
1ab Asakura, T., Lian, L., Chen, Q., Iyamu, W.E., Abdulmalik, O., Brugnara, C., and Evans, G. : Five-year summary report of screening screening new therapeutic agents for the treatment of sickle cell disease by the NIH Sickle Cell Disease Reference Laboratory. The 26th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
182 Abdulmalik, O., Hayashi, S., Chen, Q., Asakura, T., and Flake, A. W. : Evaluation of the efficacy of mixed chimerism in transgenic sickle mice that were treated with in utero hematopoietic stem cell transplantation. The 26th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
2c
7
1d
1f
Selected Publications
160 Hayashi, S., Abdulmalik, O., Peranteau, W.H., Ashizuka, S., Campagnoli, C. Chen, Q., Horiuchi, K., Asakura, T., and Flake, A.W: Mixed chimerism following in utero hematopoietic stem cell transplantation in murine models of hemlogolobinopathy. Exp. Hematol. 31: 176-184, 2003.bb Iyamu, E.W. and Asakura, T. : Drug Therapy for sickle cell disease. Exp. Opin. Ther. Patents. 13: 807-813, 2003.
179 Iyamu, E.W., Adunyah, S.E., Fasold, H., Horiuchi, K. Baliga, S. Ohene-Frempong, K., Turner, E.A., and Asakura, T. : Combined Use of Non-myelosuppressive Nitrosourea Analogues with Hydroxyurea in the Induction of F-cells production in a Human Erythroleukemic cell line. Exp. Hematol. 31: 592-600, 2003.
13a Iyamu, E.W., Turner, E.A. and Asakura, T. : The naturally occurring antisickling agent, Nix-0699, prolongs the survival time of transgenic sickle cell mice exposed to acute severe hypoxic conditions. Brit J Haematol . 122: 1001-1008, 2003.
139 Abdulmalik, O., Martin, M., Yang, J., Chen, Q., Brugnara, C., Evans, G., Abraham, D. and Asakura, T.: In vitro and in vivo studies on 5-hydroxymethyl-2-furfural (5HMF): A new potent antisickling agent. American Society of Hematology 2003.
d6 Iyamu W.E: In vitro effects of NIPRISAN (Nix-0699): a naturally occirring potent antisickling agent. Brit. J. Haematol. 118: 337-343, 2002.
179 Zhang, C., Li, X., Lian, L., Q. Chen, L.Q., Vassilev, V., C. Lai, C., Evans G, and Asakura, T: Antisickling effect of MX-1520, A prodrug of vanillin: an in vitro study using rats and transgenic sickle mice. The 26 th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
1a6 sakura, T., Ballas, S., Ohene-Frempong, K., and Lian L. : Existence of two types of reversibly sickled cells in the blood of patients with sickle cell disease: their involvment in the clinical diversity among patients and initiation of vaso-occlusion. The 26th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
1ab Asakura, T., Lian, L., Chen, Q., Iyamu, W.E., Abdulmalik, O., Brugnara, C., and Evans, G. : Five-year summary report of screening screening new therapeutic agents for the treatment of sickle cell disease by the NIH Sickle Cell Disease Reference Laboratory. The 26th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
182 Abdulmalik, O., Hayashi, S., Chen, Q., Asakura, T., and Flake, A. W. : Evaluation of the efficacy of mixed chimerism in transgenic sickle mice that were treated with in utero hematopoietic stem cell transplantation. The 26th Annual Meeting of the National Sickle Cell Disease Program. Proceeding. Abstract 2002.
2c